share_log

RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target

Benzinga ·  Sep 25, 2023 12:01

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Outperform and maintains $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment